Full Press Release Details
ASX Market Announcements ASX Limited
Stock Exchange Centre 20 Bridge Street
RESULTS OF ANNUAL GENERAL MEETING
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the attached document provides details of the proxies received and the manner in which votes were cast for each resolution.
This announcement was authorised for release by the Company Secretary.
FOR FURTHER INFORMATION PLEASE CONTACT:
Ms Suzanne Irwin Company Secretary
About Bionomics Limited
Bionomics (ASX:BNO, OTCQB:BNOEF) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system ( CNS ) disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective negative allosteric modulator of the 7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder ( SAD ) and chronic treatment of Post-Traumatic Stress Disorder ( PTSD ). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.
ANNUAL GENERAL MEETING
Wednesday, 16 November 2022
The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
| Resolution details | Instructions given to validly appointed proxies (as at proxy close) | Number of votes cast on the poll (where applicable) | Resolution Result | ||||||
| Resolution | Resolution Type | For | Against | Proxy's Discretion | Abstain | For | Against | Abstain* | Carried / Not Carried |
| 1. Adoption of Remuneration Report | Ordinary | 348,518,059 96.50% | 11,162,111 3.09% | 1,457,982 0.41% | 1,685,701 | 363,914,938 97.02% | 11,167,811 2.98% | 1,685,701 | Carried |
| 2. Re-election of Mr Alan Fisher as a Director of the Company | Ordinary | 352,110,170 97.44% | 7,829,138 2.16% | 1,460,110 0.40% | 1,988,762 | 367,584,861 97.86% | 8,029,138 2.14% | 1,988,762 | Carried |
| 3. Approval of issue of Shares Future Placement Facility | Ordinary | 348,008,029 95.87% | 13,550,209 3.73% | 1,457,982 0.40% | 371,960 | 363,480,592 96.35% | 13,750,209 3.65% | 371,960 | Carried |
| 4. Approval of 10% Placement Facility | Special | 348,746,387 96.07% | 12,792,951 3.53% | 1,457,982 0.40% | 390,860 | 364,213,250 96.55% | 12,998,651 3.45% | 390,860 | Carried |
| * Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. |